Invention Grant
- Patent Title: Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
-
Application No.: US15730997Application Date: 2017-10-12
-
Publication No.: US10221146B2Publication Date: 2019-03-05
- Inventor: Thomas D. Aicher , Chad A. VanHuis , William D. Thomas , John K. MacLean , Brian M. Andresen , Kenneth J. Barr , Corey E. Bienstock , Neville J. Anthony , Matthew Daniels , Kun Liu , Yuan Liu , Catherine M. White , Blair T. Lapointe , Nunzio Sciammetta , Vladimir Simov
- Applicant: Merck Sharp & Dohme Corp. , Lycera Corporation
- Applicant Address: US MI Ann Arbor US NJ Rahway
- Assignee: Lycera Corporation,Merck Sharp & Dohme Corp.
- Current Assignee: Lycera Corporation,Merck Sharp & Dohme Corp.
- Current Assignee Address: US MI Ann Arbor US NJ Rahway
- Agency: Dechert LLP
- Main IPC: C07D265/36
- IPC: C07D265/36 ; C07D413/14 ; C07D215/58 ; C07D401/06 ; C07D401/12 ; C07D413/04 ; C07D471/04 ; A61K31/4375 ; A61K31/47 ; A61K31/4709 ; A61K31/538 ; A61K45/06 ; C07D413/06 ; C07D413/12 ; C07D417/06 ; C07D487/04
Abstract:
The invention provides certain bicyclic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
Public/Granted literature
Information query
